top of page

Mega Biopharma Embarks on Series A Funding Round: Aiming for €15 Million to Propel Growth

Updated: Dec 4, 2023

Mega Biopharma is excited to announce the launch of our Series A funding round, with an ambitious goal of raising €15 million. This critical step forward aligns with our vision to be at the forefront of biotechnological innovation, particularly in advancing our pioneering Bionacre® technology.

The Series A funding will play a key role in accelerating our journey. These funds are earmarked for finalizing extensive studies and securing necessary certifications, setting the stage for our market entry in Europe and the US. It's not just about capital; it's about making a tangible impact in the field of biomedical technology.

This round of funding will enable us to expand our reach, enhance our research capabilities, and strengthen our market presence. We are optimistic about the support from our existing and potential investors, as we continue to push the boundaries of innovation in healthcare.

The pursuit of Series A funding is more than a financial milestone; it’s a stepping stone towards realizing our vision of transforming healthcare through advanced biotechnological solutions.

Recent Posts

See All


bottom of page